Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sj̈gren's syndrome

Rheumatology

Volumn 50, Issue 5, 2011, Pages 879-884

  He, Jing ^a   Guo, Jian Ping ^a   Ding, Yan ^a   Li, Ying Ni ^a   Pan, Si Si ^a   Liu, Yanying ^a   Li, Zhan Guo ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antibodies; ESSDAI score; Sj gren syndrome; Type 3 muscarinic acetylcholine receptor

Indexed keywords

ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; MUSCARINIC M3 RECEPTOR; POLYPEPTIDE;

ADULT; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EULAR SJOEGREN SYNDROME DISEASE ACTIVITY INDEX SCORE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; XEROPHTHALMIA; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; CHINA; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECEPTORS, MUSCARINIC; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 79955166358     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq420     Document Type: Article

References (23)

1. Fox RI, Stern M, Michelson P. Update in Sjögren's syndrome[J]. Curr Opin Rheumatol 2000;12:391-8.
2. Vitali C, Bombardieri S, Jonsson R et al. European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
3. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31.
4. 3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996;104:454-9.
5. Nguyen KHT, Brayer J, Cha S et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000; 43:2297-306.
6. Kovacs L, Marczinovits I, Gyorgy A et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 313-228 in primary Sjogren's syndrome. Rheumatology 2005;44:1021-5.
7. Cavill D, Waterman SA, Gordon TP. Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjogren's syndrome. J Rheumatol 2002;29:1342-4.
8. Tusnády GE, Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics 2001;17: 849-50.
9. Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand J Immunol 2004;59:261-6.
10. Koo N-Y, Li J, Hwang S-M et al. Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients. Rheumatology 2008;47:828-33.
11. Seror R, Ravaud P, Bowman SJ et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2010;69: 1103-9.
12. Seror R, Mariette X, Bowman S et al. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European league against rheumatism Sjogren's syndrome disease activity index. Arthrit Care Res 2010;62: 551-8.
13. Arnett FC, Edworthy S, Bloch DA et al. The American Rheumatism Association (1987) revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
15. Robinson CP, Brayer J, Yamachika S et al. Transfer of human serum IgG to nonobese diabetic Ig_null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci USA 1998;95:7538-43.
16. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2000;43:1647-54.
17. Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 2003;74:675-96.
18. 3R autoantibodies in patients with Sjögren's syndrome. Autoimmun Rev 2010;9:615-7.
19. Digby GJ, Shirey JK, Conn PJ. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst 2010;6:1345-54.
20. Gao J, Cha S, Jonsson R. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004;50: 2615-21.
21. Bacman S, Berra A, Sterin-Borda L. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci 2001;42: 321-7.
22. Bacman SR, Berra A, Sterin-Borda L, Borda ES. Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res 1998;17: 1135-42.
23. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 2001;101:249-63.